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ABSTRACT
OBJECTIVE: To estimate the incidence and to evaluate risk factors for antineoplastic nausea 
and vomiting with high and moderate emetogenic chemotherapy in adult patients in the first 
treatment cycle.
METHODS: Prospective cohort study with follow-up of 269 adults during the first cycle of 
antineoplastic chemotherapy. The incidence of nausea and vomiting was evaluated in the acute 
phase (0–24 hours), in the late phase (24 hours–5th day) and in the total phase (0–5th day).
RESULTS: In total, 152 patients underwent high emetogenic chemotherapy and 117 moderate 
emetogenic chemotherapy. The relative frequency of nausea was higher when compared 
with vomiting in the acute phase (p < 0.001) and in the late phase (p < 0.001). The risk factors 
identified were: age group ≤ 49 years (odds ratio = 0.47; 95%CI 0.23–0.95) and 50–64 years 
(odds ratio = 0.45; 95%CI 0.23–0.87), tobacco use (odds ratio = 0.35; 95%CI 0.14–0.88), and high 
emetogenic chemotherapy (odds ratio 0.55; 95%CI 0.31–0.95).
CONCLUSION: The incidence of nausea was higher than that of vomiting, and adverse 
effects were more frequent in the late phase. The results suggest the risk factors for 
chemotherapy-induced nausea and vomiting are tobacco, age (young adults), and high 
emetogenic chemotherapy. 
DESCRIPTORS: Antineoplastic, adverse effects. Nausea Vomiting, prevention and control 
Antiemetics. Neoplasias, therapy. Cohort studies.
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INTRODUCTION
Cancer is a public health issue and its prevention and control are challenges for this 
century. However, antineoplastic drugs have side effects that worsen the quality of 
life, in addition to being expensive and possibly leading to treatment discontinuation. 
Chemotherapy-induced nausea and vomiting (CINV) are the most frequent gastrointestinal 
adverse effects, despite advances in prophylactic therapies1. Nausea is described as a 
subjective, painless sensation that precedes vomiting, and vomiting is described as the 
expulsion of gastric contents through the mouth2-3.
CINV episodes can be classified according to the phase of their occurrence. The first 24 
hours after the start of chemotherapy infusion are called the “acute phase.” The period from 
24 hours to 5 days is called “late phase4.”
Among the risk factors for CINV, chemotherapy agents and combinations of agents 
are categorized as minimalEC), low (LEC), moderate (MEC), or high (HEC) emetogenic 
chemotherapy5. Other risk factors are: being a woman, having already received chemotherapy 
in previous treatments, being aged under 50 years, use of medicines, impaired emotional 
state, brain metastases, tobacco use and non-alcohol consumption6.
The risk of CINV for patients undergoing chemotherapy with HEC and MEC is estimated at 
90% and 30–90%, respectively. In Brazil, there is no antiemetic protocol established. However, 
the Consenso Brasileiro de Náuseas e Vômitos em Cuidados Paliativos (Brazilian Consensus on 
Nausea and Vomiting in Palliative Care) refers to the protocol of the Multinational Association 
for Support in Cancer Care (MASCC) and the European Society of Medical Oncology (ESMO)7. 
CINV worsens the quality of life of cancer patients, causing lack of appetite, weight loss, decreased 
social life and even more serious clinical consequences, such as dehydration and cachexia8-10.
Considering the relevance of these adverse effects, this study aims was to estimate the 
incidence and evaluate the risk factors for antineoplastic chemotherapy-induced nausea 
and vomiting with high and moderate emetogenic chemotherapy in adult patients in the 
first treatment cycle.
METHODS
Prospective cohort study with patients who started chemotherapy between June and 
December 2015 in three reference oncology hospitals in the city of Belo Horizonte (MG), 
whose estimated population is 2,238,526 inhabitants11. A pilot study was carried out from 
January to June of the same year.
We considered eligible cancer patients, older than 18 years, both men and women and 
who were receiving chemotherapy for the first time. Patients with nausea or vomiting 24 
hours before chemotherapy, who underwent abdominal radiotherapy concomitantly with 
chemotherapy, and those with inability to verbal communication were excluded. Participants 
underwent one-day chemotherapy protocols, followed up in the first treatment cycle until 
the fifth day after chemotherapy infusion, and they were interviewed again in the next 
chemotherapy cycle.
In the first stage of the expanded research project, a structured questionnaire containing 
questions on socioeconomic, demographic, clinical, and quality of life (EuroQol Research 
Foundation 5 Dimensions and European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 version 3.0) was answered by patients undergoing the 
first cycle of chemotherapy. Both questionnaires were validated for Brazilian Portuguese. 
The quality of life results will be described in later publications.
In the second stage, on the return to perform the second cycle of chemotherapy, data on 
quality of life were collected again, and the patients delivered the questionnaire of the 
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experiences of nausea and vomiting in the period of five days. The presence of nausea 
and vomiting (yes/no) and the number of vomiting episodes per day were measured. 
Patients who did not return for the second cycle of chemotherapy were contacted by 
telephone and their medical records were reviewed to verify the reason for the loss to 
follow-up. Clinical variables of interest were also collected from medical records. The 
explanatory variables used were: gender, race/skin color, age, marital status, schooling, 
primary neoplasia, stage, presence of metastasis, alcohol and/or tobacco consumption, 
radiotherapy, source for treatment costing and antiemetic regimen in the late phase. The 
control variables were: emetogenic chemotherapy, treatment hospital and antiemetic 
regimen in the acute phase. The outcome variables were: acute and late nausea, acute 
and late vomiting.
Complete response to nausea and vomiting was defined as absence of nausea and vomiting. 
Complete response to vomiting was defined as no occurrence of vomiting. Absence of 
nausea defined a complete response to nausea. It was considered as acute phase up to 
24 hours from the beginning of chemotherapy infusion, from 24 hours to five days was 
considered a late phase, and from beginning of chemotherapy infusion to the fifth day, the 
total phase. Antiemetic prophylaxis was classified as adequate or inadequate according to 
the international protocol of MASCC and ESMO5.
The sample was estimated considering the patients in their exposure group in HEC and 
MEC (Openepi® program),95% confidence level; 95% power; and percentage of positive 
exposures provided by the literature (HEC 90%, MEC 60%). The estimated sample consisted 
of 116 participants, 58 for each group.
Descriptive and inferential statistical analysis was performed. In the bivariate analysis, the 
chi-square test (X2) or Fisher’s exact test were used. McNemar test was used for dependent 
samples. The multiple models (acute phase, late phase and total phase) were controlled by 
the variables “hospital,” “emetogenic chemotherapy,” and “antiemetic” in the acute phase. 
The variables presenting p-value < 0.20 in at least one of the phases of bivariate analysis 
and absence of collinearity participated in the multiple logistic regression model. A p < 0.05 
was considered as statistically significant value. The statistical analyses were conducted 
using the Statistical Package for the Social Sciences, version 20.
The study was approved by the Research Ethics Committee of the Universidade Federal de 
Minas Gerais and by the co-participating hospitals (Certificate of Presentation for Ethical 
Appreciation – CAAE: 36059514.5.0000.514). All participants signed the informed consent 
form. The illiterate gave their consent by fingerprinting, and the term was read in the 
presence of a relative.
RESULTS 
In total, 549 patients started outpatient treatment with chemotherapy in the three 
hospitals, during the study period. A total of 201 patients were excluded at the beginning 
of data collection. The reasons for exclusion were: age ≤ 18 years (two patients); previous 
chemotherapy (66 patients); nausea/vomiting in the previous 24 hours (19 patients), 
abdominal radiotherapy (18 patients), drug-induced drowsiness (23 patients), inability 
to communicate (52 patients); refusal to participate (15 patients), and chemotherapy for 
another disease (six patients).
Thus, 348 patients were eligible for follow-up, and 49 patients were lost to follow-up. The 
reasons for loss to follow-up were: discontinuation of chemotherapy treatment (12 patients); 
death (two patients); incomplete questionnaire (29 patients); and hospitalization for 
chemotherapy in the second cycle (six patients). The final analysis was performed with 
269 participants, 152 undergoing HEC and 117 undergoing MEC. However, we present the 
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Table 1. Distribution of clinical, sociodemographic, life habits and emetogenic chemotherapy of 


















Female 86 (56.6) 87 (74.4) 14 (50) 1 (50) 188 (62.9)
Age (years)
Mean (SD) 54.6 (13.0) 56.0 (12.3) 64.3 (13.5) 50.5 (14.8) 56.0 (13.0)
Median 56 55 64.5 50.5 57.0
Minimum–Maximum 20–86 32–83 31–88 40–61 20–88
Age group
≤ 49 45 (29.6) 40 (34.2) 4 (14.3) 1 (50.0) 90 (30.1)
50–64 74 (48.7) 46 (39.3) 10 (35.7) 1 (50.0) 131 (43.8)
≥ 65 33 (21.7) 31 (26.5) 14 (50.0) 0 78 (26.1)
Ethnicity/Color 
Brown skin 88 (57.8) 65 (55.5) 16 (57.2) 1 (50.0) 170 (56.9)
White 38 (25.0) 33 (28.2) 6 (21.4) 1 (50.0) 78 (26.1)
Black 17 (11.2) 17 (14.5) 4 (14.3) 0 38 (12.7)
Asian 7 (4.6) 1 (0.9) 2 (7.1) 0 10 (3.3)
Indigenous 1 (0.7) 1 (0.9) 0 0 2 (0.7)
No record 1 (0.7) – – – 1 (0.3)
Marital status
Married 72 (47.3) 65 (55.6) 17 (60.7) 1 (50.0) 155 (51.8)
Single 33 (21.7) 26 (22.2) 3 (10.7) 1 (50.0) 63 (21.1)
Divorced 27 (17.8) 15 (12.8) 5 (17.9) 0 47 (15.7)
Widow/widower 20 (13.2) 11 (9.4) 3 (10.7) 0 34 (11.4)
Schooling (years) 
Mean (SD) 5.7 (3.5) 7 (4.2) 5.3 (4.2) 13.5 (3.5) 6.2 (4.3)
Median 4.0 6.7 4.0 13.5 5.0
Minimum – Maximum 0–16 0–20 0–14 11–16 0–20
Illiterate 18 (11.8) 4 (3.4) 5 (17.9) 0 27 (9.0)
4 64 (42.1) 42 (36.0) 13 (46.4) 0 119 (39.8)
5–8 31 (20.4) 30 (25.6) 2 (7.1) 0 63 (21.1)
9–12 29 (19.1) 31 (26.5) 7 (25.0) 1 (50.0) 68 (22.7)
≥ 13 8 (5.3) 9 (7.7) 1 (3.6) 1 (50.0) 19 (6.4)
No record 2 (1.3) 1 (0.8) – – 3 (1.0)
Clinical Characteristics
Primary neoplasm
Breast 0 56 (47.8) 1 (3.6) 0 57 (19.1)
Colon and rectum 0 31 (26.5) 16 (57.1) 0 47 (15.7)
Cervical 44 (28.9) 0 0 0 44 (14.7)
HNF: 41 (27.0) 0 0 0 41 (13.7)
Lung 22 (14.5) 9 (7.7) 0 0 31 (10.4)
Esophagus/stomach 11 (7.3) 7 (6.0) 3 (10.7) 0 21 (7.0)
Ovary 9 (5.9) 5 (4.3) 0 0 14 (4.7)
Lymphoma 3 (2.0) 5 (4.3) 0 2 (100.0) 10 (3.3)
Others 22 (14.5) 4 (3.4) 8 (28.6) 0 34 (11.3)   
Continue
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descriptive analysis for the sample with all emetogenic chemotherapies followed. The other 
participants underwent other emetogenic chemotherapies.
Most participants were women, with a mean age of 55.2 years, brown-skinned, married, 
with an average 6.2 years of schooling and undergoing chemotherapy with HEC. Breast 
cancer was the most frequent primary neoplasm. The sociodemographic, clinical, and 
treatment-related characteristics are shown in Table 1.
The chemotherapy protocols were: CDDP (Cisplatin), 87 (32.3%); AC (Cyclophosphamide 
< 1500mg/m2 and Doxorubicin), 49 (18.2%); CDDP-P (Cisplatin and Paclitaxel), 23 (8.6%); 
Carboplatin and Paclitaxel, 21 (7.8%); FOLFOX (5-Fluouracil and Leucovorin), 18 (6.7%); 
Cisplatin and Fluouracil, 11 (4.1%); PE (Cisplatin and Etoposide), 7 (2.6%); R-CHOP, 4 (1.5%); 
FLOX, 4 (1.5%); and others, 45 (16.7%). 
The prophylaxis of prescribed antiemetics was inadequate for the acute phase and for the 
late phase, considering the MASCC and ESMO protocol for all patients.
Note that, in the acute phase, all patients received prophylactic infusion of intravenous 
antiemetics in the hospital. Out of these, 151 (99.3%) patients undergoing chemotherapy with 
HEC and 117 (100%) patients undergoing chemotherapy with MEC received ondansetron 
(5-HT3RA). Dexamethasone was administered to 149 (98%) patients undergoing HEC 
chemotherapy and in 114 (97.4%) undergoing MEC. Also, ranitidine was administered to 31 
(20.4%) patients undergoing chemotherapy with HEC and to 31 (26.5%) patients undergoing 
MEC. Omeprazole was administered to 10 (6.6%) patients, dimehydrinate to 16 (10.5%) and 
metoclopramide to 12 (10.3%). No patient received neurokinin antagonist (NK1). 
Table 1. Distribution of clinical, sociodemographic, life habits and emetogenic chemotherapy of chemotherapy 
characteristics. Belo Horizonte (MG), Brazil, 2015. Continuation
Stage
I 12 (7.9) 7 (6.0) 0 0 19 (6.4)
II 21 (13.8) 29 (24.7) 6 (21.4) 0 56 (18.7)
III 50 (32.9) 54 (46.2) 10 (35.7) 1 (50.0) 115 (38.5)
IV 54 (35.5) 23 (19.6) 10 (35.7) 1 (50.0) 88 (29.4)
Not registered 15 (9.9) 4 (3.5) 2 (7.2) – 21 (7.0)
Metastasis 65 (42.8) 54 (46.2) 17 (60.7) 2 (100.0) 138 (46.1)
Life Habits
Alcohol 
Currently 14 (9.2) 21 (17.9) 4 (14.3) 0 39 (13.0)
Before treatment 81 (53.3) 47 (40.2) 11 (39.3) 1 (50.0) 140 (46.9)
Never 57 (37.5) 49 (41.9) 13 (46.4) 1 (50.0) 120 (40.1)
Tobacco
Currently 22 (14.5) 9 (7.7) 3 (10.7) 0 34 (11.4)
Before treatment 72 (47.3) 47 (40.2) 10 (35.7) 1 (50.0) 130 (43.5)
Never 58 (38.2) 61 (52.1) 15 (53.6) 1 (50.0) 135 (45.1)
Treatment
Radiotherapy 94 (61.8) 9 (7.7) 5 (17.9) 0 108 (36.1)
Chemo costing
SUS 148 (97.4) 105 (89.7) 26 (92.9) 1 (50.0) 280 (93.7)
Health insurance plan 3 (2.0) 8 (6.8) 0 1 (50.0) 12 (4.0)
Private 0 2 (1.7) 2 (7.1) 0 4 (1.3)
No record 1 (0.6) 2 (1.7) – – 3 (1.0)
HEC: high emetogenic chemotherapy; MEC: moderate emetogenic chemotherapy; LEC: low emetogenic 
chemotherapy; UEC: unclassified emetogenic chemotherapy; SD: standard deviation II; HN: head and neck; 
Chemo: chemotherapy; SUS: Brazilian Unified Health System.
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In the late phase, 139 (91.4%) patients undergoing chemotherapy with HEC and 103 (88%) of 
the patients undergoing MEC chemotherapy were prescribed antiemetics for consumption 
at home. Ondansetron was prescribed for 111 (79.9%) patients undergoing chemotherapy 
with HEC and 90 (87.4%) patients undergoing MEC. Dexamethasone was prescribed for 61 
(43.9%) and 52 (50.5%) patients undergoing HEC and MEC, respectively. Metoclopramide was 
prescribed for 100 (71.9%) patients undergoing HEC and for 68 (66%) patients undergoing 
MEC. Omeprazole was prescribed for 10 (7.2%) and 11 (10.7%) undergoing HEC and MEC, 
respectively. Bromopride was prescribed for 9 (6.5%) and 6 (5.8%) undergoing HEC and 
MEC, respectively. Dimenhydrinate was prescribed for 15 patients (nine HEC and six 
MEC), diphenhydramine for four patients, bromopride for two (one HEC and one MEC), 
domperidone for 1 patient undergoing MEC and draminate for four (three MEC and one 
HEC. NK1 antagonist was not prescribed for any patient.
The incidence of nausea for all participants in the total phase was 58%, and the incidence 
of vomiting was 32.7%. In the acute phase, the incidence of nausea was 31%, and vomiting 
was 11.2%. The incidence of nausea in the late phase was 54.6%, and vomiting was 29.3%.
The incidence of nausea for HEC and MEC in the total phase was 63.2% and 51.3%, and 
vomiting was 45.8% and 19.7%, respectively. In the acute phase, the incidence of nausea for 
HEC and MEC was 35.1% and 25.6%, and vomiting was 15.2% and 6%, respectively. In the 
late phase, the incidence of nausea for HEC and MEC was 59.2% and 48.7%, and vomiting 
was 38.8% and 17.1%, respectively.
The daily relative frequency showed that, for both outcomes, participants undergoing 
chemotherapy with HEC presented higher values when compared with patients undergoing 
MEC chemotherapy. The daily relative frequency of CINV is shown in Figure 1. 
The relative frequency of nausea was higher when compared with vomiting in the acute 
phase (p < 0.001) and in the late phase (p < 0.001).
In the acute phase, among the 11.2% of patients who had vomiting, the mean number of 
vomiting was 2.7; median of 2.0, minimum of 1 and maximum of 7 vomiting. In the late 
phase, among the 29.3% of patients who had vomiting, the average number was 16; median 





























































Days after chemotherapy infusion
HEC: high emetogenic chemotherapy; MEC: moderate emetogenic chemotherapy.
Figure. Relative frequency of nausea and vomiting during the five-day period after chemotherapy 
infusion. Belo Horizonte (MG), Brazil, 2015.
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The proportion of complete responses for nausea and vomiting was statistically different 
between the emetogenic chemotherapies, for the total phase. In the acute phase, a statistically 
significant difference was observed only for the complete response to vomiting between the 
two groups of emetogenic chemotherapy. In the late phase, there was a difference between 
the groups of patients who received HEC and MEC for vomiting, as shown in Table 2.
Sociodemographic, clinical factors, lifestyle habits, and treatments associated with complete 
response to antineoplastic chemotherapy-induced nausea and vomiting were stratified by 
treatment phase, and they are presented in Table 3.
In the bivariate analysis, differences in the complete response to CINV were observed in 
the acute phase regarding the variables tobacco use and hospital treatment. In the acute 
phase, a lower proportion of complete response was identified in Hospital 2 (64.7%) compared 
with the other two hospitals, and among smokers (41.9%), compared with patients who had 
never smoked or who are former smokers. In the total phase, the variables age group and 
emetogenic chemotherapy showed statistically significant differences. In the total phase, 
the age group younger than 49 years had a lower incidence of complete response (32.9%), 
and patients undergoing chemotherapy with HEC had lower complete response (32.2%) 
compared with patients undergoing MEC. The bivariate analysis can be verified in Table 3.
In the total phase, the lower age groups (≤ 49 years and 50–64 years) decreased the complete 
response compared with the upper age group (≥ 65 years) – odds ratio (OR) = 0.47; 95% 
confidence interval (95%CI) 0.23–0.95 versus OR = 0.45; 95%CI 0.23–0.87. The complete 
response also increases in this phase when we compare patients who have never smoked 
with former smokers (OR = 1.91; 95%CI 1.02–3.57). Also in this phase, the complete response 
decreased in patients undergoing chemotherapy with HEC, when compared with patients 
undergoing MEC (OR = 0.55; 95%CI 0.31–0.95).
Multiple logistic regression showed that, in the acute phase, smoking decreases the complete 
response compared to patients who had never smoked (OR = 0.35; 95%CI 0.14–0.88). Hospital 
1 showed a better complete response in the acute phase, when compared to Hospital 3 
(OR = 2.71; 95%CI 1.14–6.42).
In the late phase, the complete response decreases in patients undergoing chemotherapy 
with HEC, when compared with patients undergoing MEC (OR = 0.56; 95%CI 0.32–0.97). 
The variables inserted in the multiple logistic regression model are presented in Table 4.
Table 2. Incidence of complete response to antineoplastic chemotherapy-induced nausea and vomiting 
according to the occurrence phase and emetogenic chemotherapy. Belo Horizonte (MG) Brazil, 2015.
Emetogenic chemotherapy n = 269
p*HEC
(n = 152; 56.5%)
MEC
(n = 117; 43.5%)
Complete phase (acute/late phase)
Complete nausea and vomiting Response 49 (32.2) 55 (47.0) 0.014
Complete vomiting response 87 (57.2) 94 (80.3) < 0.001
Complete nausea response 56 (36.8) 57 (48.7) 0.050
Acute phase
Complete nausea and vomiting Response 97 (64.2) 86 (73.5) 0.106
Complete vomiting response 128 (84.8) 110 (94.0) 0.017
Complete nausea response 98 (64.9) 87 (74.4) 0.097
Late phase
Complete nausea and vomiting Response 56 (36.8) 57 (48.7) 0.050
Complete vomiting response 93 (61.2) 97 (82.9) < 0.001
Complete nausea response 62 (40.8) 60 (51.3) 0.087
HEC: high emetogenic chemotherapy; MEC: moderate emetogenic chemotherapy. 
* Chi-square test.
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Table 3. Complete response to nausea/vomiting according to sociodemographic, clinical, and treatment phase variables. Belo Horizonte 
(MG), Brazil, 2015.
Complete Nausea/vomiting response

















Female 172 (67.4) 0.692 173 (38.7) 0.144 173 (37.0) 0.451
Male 96 (69.8) 96 (47.9) 96 (41.7)
Age group
≤ 49 84 (69.0) 0.317 85 (35.3) 0.085 85 (32.9) 0.024
50–64 120 (64.2) 120 (40.8) 120 (35.0)
≥ 65 64 (75.0) 64 (53.1) 64 (53.1)
Marital status
Married 137 (67.2) 0.326 137 (37.2) 0.363 137 (35.0) 0.242
Single 59 (74.6) 59 (47.5) 59 (44.1)
Divorced 41 (58.5) 42 (42.9) 42 (33.3)
Widow/widower 31 (74.2) 31 (51.6) 31 (51.6)
Schooling (years) 
Illiterate 22 (59.1) 0.637 22 (40.9) 0.681 22 (40.9) 0.803
4 106 (67.0) 106 (44.3) 106 (40.6)
5–8 61 (75.4) 61 (42.6) 61 (41.0)
9–12 59 (66.1) 60 (35.0) 60 (31.7)
≥ 13 17 (6.4) 17 (52.9) 17 (41.2)
Stage
I 19 (73.7) 0.387 19 (36.8) 0.260 19 (36.8) 0.670
II 50 (58.0) 50 (32.0) 50 (32.0)
III 103 (68.9) 104 (43.3) 104 (39.4)
IV 77 (71.4) 77 949.4) 77 (42.9)
Metastasis
Yes 119 (70.6) 0.469 119 (42.0) 0.998 119 (38.7) 0.999
No 149 (66.4) 150 (42.0) 150 (38.7)
Alcohol 
Currently 35 (80.0) 0.271 35 (42.9) 0.782 35 (42.9) 0.663
Former smoker 128 (67.2) 128 (39.8) 128 (35.9)
Never 105 (65.7) 106 (44.3) 106 (40.6)
Tobacco
Currently 31 (41.9) 0.002 31 (29.0) 0.086 31 (22.6) 0.051
Former smoker 119 (75.6) 119 (48.7) 119 (51.9)
Never smoked 118 (67.8) 119 (38.7) 119 (36.1)
Chemotherapy costing
SUS 252 (67.6) 0.476 253 (41.5) 0.648 253 (38.3) 0.605
Health insurance plan 13 (76.9) 13 (46.2) 13 (38.5)
Access to antiemetics at home 
Purchased/did not purchase 157 (65.0) 0.165 157 (40.1) 0.460 157 (37.6) 0.666
Did not purchase 111 (73.0) 112 (44.6) 112 (40.2)
Hospital 
Hospital 1 69 (84.0) 0.015 69 (47.8) 0.642 69 (47.8) 0.513
Hospital 2 139 (64.7) 140 (46.4) 140 (40.0)
Hospital 3 90 (68.8) 90 (41.1) 90 (40.0)
Continue
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Table 4. Multiple logistic regression for complete response of nausea/vomiting. Belo Horizonte (MG), Brazil, 2015.
Factors
Complete nausea/vomiting response
Acute phase Late phase Total phase








Female 1 1 1
Age group





0.0350–64 0.65 (0.32–1.35) 0.54 (0.28–1.05) 0.45 (0.23–0.87)
≥ 65 1 1 1
Alcohol 





0.08Alcoholic 2.08 (0.76–5.70) 0.77 (0.33–1.79) 0.90 (0.38–2.1)
Nonalcoholic 1 1 1
Tobacco





0.04Smoker 0.35 (0.14–0.88) 0.91(0.35–2.35) 0.75 (0.27–2.05)








MEC 1 1 1
Acute Phase Antiemetic






Dexamethasone + Ondansetron 0.94 (0.46–1.93) 0.66 (0.35–1.27) 0.77 (0.40–1.48)









0.78Hospital 2 0.90 (0.47–1.72) 1.17 (0.63–2.20) 0.96 (0.50–1.82)
Hospital 3 1 1 1
OR: odds ratio; 95%CI: confidence interval; HEC: high emetogenic chemotherapy; MEC: moderate emetogenic chemotherapy.
a p model: multiple logistic regression.  
b Simplified scheme: ondansetron + another antiemetic or dexamethasone + other antiemetic or ondansetron.
Table 3. Complete response to nausea/vomiting according to sociodemographic, clinical, and treatment phase variables. Belo Horizonte (MG), Brazil, 
2015. Continuation
Emetogenic chemotherapy
Hec 151 (64.2) 0.106 152 (36.8) 0.05 152 (32.2) 0.014
Mec 117 (73.5) 117 (48.7) 117 (47.0)
Acute phase antiemetic
Simplified scheme 7 (71.4) 0.820 7 (71.4) 0.071 7 (57.1) 0.209
Dexamethasone + ondansetron 200 (67.0) 201 (38.3) 201 (35.8)
Dexamethasone + Ondansetron + other 61 (72.1) 61 (51.0) 61 (46.0)
Late phase antiemetic
Ondansetrona and others - 78 (38.5) 0.505 78 (30.8) 0.313
Dexamethasone + Ondansetron + other antiemetics - 73 (43.8) 73(42.5)
Other antiemeticsb - 34 (29.4) 34 (29.4)
Dexamethasone + ondansetron - 31 (41.9) 31 (35.5)
Ondansetron - 16 (37.5) 16 (37.5)
Dexamethasone and others - 7 (71.4) 7 (71.4)
Dexamethasone - 2 (50.0) 2 (50.0)
SUS: Unified Health System; HEC: high emetogenic chemotherapy; MEC: moderate emetogenic chemotherapy. 
a Fisher’s exact test or chi-square test
b other antiemetics: h2 antagonist (diphenhydramine, dimenhydrinate, bromopride, omeprazole, ranitidine) and dopamine receptor antagonist (metoclopramide).
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DISCUSSION
The sample was mostly composed of women, with stage III breast cancer, aged between 
50 and 64 years, married, with up to four years of schooling, former smokers and former 
alcoholics, with treatment funded by the Unified Health System (SUS). The incidence of 
nausea for both emetogenic chemotherapies in the total phase was 58%, and the incidence 
of vomiting was 32.7%.
Breast cancer was the most frequent in women (33.1%), as found in prospective observational 
studies that evaluated CINV9-10,12-14. Breast cancer is the most common among women 
both in Brazil and worldwide, and mortality caused by it may be associated with social 
inequalities15,16. Furthermore, 94.1% of chemotherapy costs was funded by SUS, and 67.9% 
of the patients presented themselves with advanced stage of the disease (stage III and IV), 
initiating chemotherapy treatment. These data corroborate the official estimate of cancer 
incidence in Brazil, in which it is emphasized that cancers, including breast cancers, which 
have screening, are diagnosed in an advanced stage17.
The incidence of CINV in the acute phase was lower than in the late phase, with a peak on 
the third day (43.5%) after chemotherapy infusion, for both emetogenic chemotherapies. 
A similar result was highlighted in previous studies, in which the incidence of nausea and 
vomiting was lower in the acute phase9,13.
Nausea is a subjective adverse effect, but it is more frequent than vomiting, and with 
the potential for worsening quality of life and nutritional status of patients undergoing 
chemotherapy18. Non-pharmacological therapies are indicated for the control of nausea, 
such as distraction techniques and ginger consumption19-20. 
Acute nausea presented a lower incidence (31%) when compared with a recent study13 (46%) 
which was composed of patients who were also undergoing both emetogenic chemotherapies 
(HEC and MEC). The occurrence of late nausea (54.6%) was also lower than that reported 
in the aforementioned study, which found an incidence of 82.7%13.
In our study, the complete response to vomiting was 61.2% and nausea was 40.8% in patients 
undergoing HEC in the acute phase. Higher frequencies for complete vomiting response 
(86%) and nausea (81%) have been observed in previous studies12.
The occurrence of vomiting (29.4%) in the late phase was higher than that found in a 
previous study (23%)13-14. When comparing the incidence of late vomiting by emetogenic 
chemotherapy (HEC: 38.8% and MEC: 17.1%) we also found a higher proportion than that 
found by other authors (19.2% for HEC and 16.1% for MEC)12.
The complete response to vomiting in the total phase was 57.2% for patients undergoing 
HEC and 80.3% for patients undergoing MEC. In a previous study12, the complete 
response to vomiting was 74.8% in patients undergoing HEC, a percentage higher than 
that found in this study. However, the complete response for patients undergoing MEC 
was similar, 80%12. 
The complete response to CINV in the total phase was observed for 38.7% of the patients, 
after undergoing antineoplastic chemotherapy with HEC and MEC. This proportion was 
lower when compared with those found in previous studies, in which the complete response 
in the first cycle was 53.4%21 and 69%12.
In our study, no patient received an antiemetic regimen with NK1 receptor antagonist. 
In a previous study13, the antiemetic regimen 5-HT3RA + dexamethasone was prescribed for 
62.9% patients, and the 5-HT3RA regimen was prescribed for 18.2%, and 78.6% of patients 
received antiemetic regimen recommended by the protocol. In another study21, during the 
first cycle of chemotherapy, the adequacy of antiemetic prescription to the protocol was 
63.4% in the acute phase and 59.7% in the late phase. 
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Note that antiemetic regimens are not prescribed according to protocols. We found no 
association between the prescribed regimens and the complete response for different phases 
analyzed. Note that more recent studies have shown that antiemetic regimens composed 
of the association of 5-HT3RA + NK1 antagonist and corticosteroids have better controlled 
CINV in both acute and late phases22,23. Patients who received chemotherapy with HEC 
presented lower complete responses for late and total phase, in comparison with patients 
undergoing MEC, corroborating the previous literature21,24.
The lower age groups (≤ 49 and 50-64 years) were a risk factor for CINV. These results were 
similar in previous studies, in which age groups below 50–55 years showed worsening of 
the complete response to CINV14,21,24,25. 
A previous study showed that CINV were less frequent among smoking patients compared 
with non-smokers26. In our study, in the late and total phases, there was an inverse association 
between former smokers and presenting a better complete response, compared to patients 
who had never smoked. Previous contact with tobacco and non-current smoking was a 
negative factor for CINV. However, one study emphasized the harms of smoking for cancer 
patients undergoing chemotherapy, among them: weight loss, skin and sleep complications 
and incidence of nausea, compared with patients who did not smoke27. 
No evidence was found relating women as a risk factor for CINV, which corroborates the 
previous result21,28. However, some studies indicate that women would be more susceptible 
to CINV14.
No difference in CINV was found between users and non-users of alcohol . The consumption 
of five or more doses of alcohol per week was associated with complete response to vomiting 
in a previous study28. Another study found an association, in the first cycle of chemotherapy, 
for patients who consumed more than 11 doses of alcohol per week for the outcome of acute 
vomiting, compared with patients who did not consume alcohol or doses per week, with the 
highest alcohol consumption being a protective factor against CINV. Alcohol consumption 
was not associated with a difference in response to NCIV in previous literature24.
Hospital 1 has a characteristic that differentiates it, which may have influenced the 
increase in the complete response to acute phase compared with Hospital 3. An association 
was found between the hospital and the antiemetic regimen administered to the patient in 
the acute phase. Hospital 1 patients received 5-HT3RA + corticosteroid + other antiemetic 
regimen (closer to what is recommended by the MASCC and ESMO protocols) in 39.3% 
of the cases. 
Some factors not researched until now may have influenced the improvement of complete 
response to nausea and vomiting in the acute phase in Hospital 1, compared with 
Hospital 3. Specifically for the control of nausea and vomiting, the physical structure 
of the chemotherapy rooms (ventilation, odors, stay of the patients’ companion) can be 
highlighted. The cerebral cortex identifies some factors related to the hospital environment 
that can induce nausea and vomiting3. Previous studies have found an association between 
the support of the caretaker/family member perceived by the patient and the response 
to NCIV control29. It is known that other resources may influence the control of nausea 
and vomiting, such as acupuncture, ginger consumption, fractional and cold feeding, and 
relaxation and distraction techniques – which was not investigated in this study and may 
have predominated in the participants of Hospital 130.
Among the limitations of our study, the absence of any measure on dose of alcohol 
consumption stands out. The variable “use of antiemetic rescue use” in households was not 
used, as there could be memory bias of the participants (the use of medications was not 
included in the recall questionnaire of the experiences of nausea and vomiting).
In this study, the incidence of nausea was higher than that of vomiting, and the late phase had 
a higher frequency of both adverse effects. The results suggest that tobacco, young age and 
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high emetogenic chemotherapy are among the risk factors for episodes of CINV. The treatment 
occurring in Hospital 1 was related to a better complete response in the acute phase compared 
to Hospital 3. All patients received antiemetic prophylaxis in the acute phase, although the 
prescription of antiemetic regimens did not meet the protocols used in this study as a reference 
for patients undergoing high and moderate emetogenic chemotherapy. 
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